trial

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

NCTId NCT04860830
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 609 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2024-10-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
609 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2021-08-09
Primary completion
2024-10-28
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Iclepertin

Sponsors

Boehringer IngelheimLead Sponsor

Sites

110 total
Anaheim, United StatesCulver City, United StatesLos Angeles, United StatesPico Rivera, United StatesStanford, United StatesWalnut Creek, United StatesHollywood, United StatesMaitland, United StatesMiami, United StatesMiami, United StatesOrlando, United StatesAtlanta, United States

Linked catalysts

1
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in Peo — primary completion2024-10-28

Facts & assertions

4 sourced
Enrollment
609
Phase
PHASE3
Primary Completion Date
2024-10-28
Status
COMPLETED
relationships
The graph out of here
drug
Iclepertin
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication